Breaking News Instant updates and real-time market news.

MAR

Marriott

$121.78

-0.38 (-0.31%)

, SFM

Sprouts Farmers Market

$27.03

0.4 (1.50%)

08:57
11/30/18
11/30
08:57
11/30/18
08:57

Fly Intel: Pre-market Movers

UP AFTER EARNINGS: Ambarella (AMBA), up 15%... VMware (VMW), up 5%... Workday (WDAY), up 8%... Splunk (SPLK), up 4.5%. ALSO HIGHER: Himax (HIMX), up 4% after its chairman Biing-Seng Wu announced that he intends to use his personal funds to purchase up to approximately $5M of the company's American Depositary Shares in the open market. DOWN AFTER EARNINGS: LabCorp. (LH), down 5.5%... GameStop (GME), down 10%... PVH Corp. (PVH), down 2%. ALSO LOWER: Marriott (MAR), down 4.5% after announcing a data breach affecting 327M guests that includes addresses and passport numbers... Sprouts Farmers Market (SFM), down 13% after after announcing the departure of CEO Amin Maredia.

MAR

Marriott

$121.78

-0.38 (-0.31%)

SFM

Sprouts Farmers Market

$27.03

0.4 (1.50%)

AMBA

Ambarella

$33.83

-0.81 (-2.34%)

VMW

VMware

$161.63

1.78 (1.11%)

WDAY

Workday

$145.55

-0.24 (-0.16%)

SPLK

Splunk

$102.00

2.77 (2.79%)

HIMX

Himax

$4.11

0.08 (1.99%)

LH

LabCorp

$161.78

-3.22 (-1.95%)

GME

GameStop

$14.65

-0.37 (-2.46%)

PVH

PVH Corp.

$109.82

-1.15 (-1.04%)

  • 30

    Nov

  • 30

    Nov

  • 03

    Dec

  • 03

    Dec

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 10

    Dec

  • 11

    Dec

  • 09

    Jan

  • 10

    Jan

MAR Marriott
$121.78

-0.38 (-0.31%)

11/27/18
11/27/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Outperform from In-Line at Imperial Capital with analyst David Miller saying while fiscal 2019 should be a "transitional year," fiscal 2020 brings an "abundance of catalysts." 2. Citizens Financial (CFG) upgraded to Outperform from Neutral at Macquarie. 3. Parsley Energy (PE) upgraded to Buy from Neutral at Goldman Sachs with analyst John Nelson saying greater appreciation of the the company's free cash flow inflection in the second half of 2019 should drive improved investor sentiment. 4. Taubman Centers (TCO) was upgraded to Sector Perform from Underperform at Scotiabank and to Equal Weight from Underweight at Morgan Stanley. 5. Marriott (MAR) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Stephen Grambling saying the stock has been penalized recently amid Starwood integration issues, but these will prove temporary and position Marriott better in the future. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/27/18
GSCO
11/27/18
DOWNGRADE
Target $70
GSCO
Buy
Wyndham Hotels & Resorts downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Stephen Grambling removed Wyndham Hotels & Resorts (WYN) from his firm's America's Conviction List while keeping a Buy rating on the shares. The analyst lowered his price target for the stock to $70 from $76. Grambling reduced his estimates for Wyndham to reflect incremental caution around timeshare amid softening housing data and rising rates. However, he continues to believe upside from the La Quinta acquisition, accelerating unit growth, and fee rates should all drive upside to consensus estimates and a "re-rating" versus peers. Nonetheless, Grambling sees a more attractive risk/reward in shares of Marriott (MAR).
11/27/18
GSCO
11/27/18
UPGRADE
GSCO
Conviction Buy
Marriott upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Stephen Grambling added Marriott International to his firm's America's Conviction List while keeping a Buy rating on the shares. The analyst lowered his price target for the shares to $153 from $159. The stock has been penalized recently amid Starwood integration issues, but these will prove temporary and position Marriott better in the future, Grambling tells investors in a research note. He believes that as the disruption normalizes, net unit growth should accelerate and Marriott should post upside to consensus estimates.
11/20/18
ARGS
11/20/18
DOWNGRADE
ARGS
Hold
Marriott downgraded to Hold from Buy at Argus
Argus analyst John Staszak downgraded Marriott (MAR) to Hold, citing a recent slowdown in its RevPAR growth as well as the potential for the multi-year upturn in the lodging industry to end. The analyst states that the company's latest EPS beat reflected stock repurchases and "carefully managed expenses", as revenue fell 1% and North America RevPAR was up just 0.6% and below the management's prior guidance of 1.5%-2.0% growth. Staszak adds that Marriott shares have rallied over 200% since his upgrade in 2012, but believes that other consumer discretionary names such as McDonalds (MCD) offer greater return prospects.
SFM Sprouts Farmers Market
$27.03

0.4 (1.50%)

11/16/18
BERN
11/16/18
INITIATION
Target $23
BERN
Underperform
Sprouts Farmers Market initiated with an Underperform at Bernstein
Bernstein initiated Sprouts Farmers Market with an Underperform and $23 price target.
11/16/18
11/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Adobe (ADBE) initiated with a Buy at Nomura Instinet. 2. Target (TGT) was initiated with a Buy at Buckingham and an Overweight at KeyBanc. 3. Viad (VVI) initiated with a Buy at Janney Montgomery Scott. 4. Selective Insurance (SIGI) initiated with a Market Perform at JMP Securities. 5. Sprouts Farmers Market (SFM) initiated with an Underperform at Bernstein. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/30/18
LOOP
11/30/18
NO CHANGE
Target $29
LOOP
Hold
CEO departure at Sprouts Farmers Market not a sign of problem, says Loop Capital
Loop Capital analyst Andrew Wolf kept his Hold rating and $29 price target on Sprouts Farmers Market after its announcement that CEO Amin Maredia is stepping down at the end of the year. While the news was "abrupt", the analyst notes that his conversations with the company's management indicates that its positive outlook "should remain intact". Wolf also contends that Sprouts' relative valuation is "reasonable" based on its fundamental growth outlook, even though the stock is the "highest valued member" of his Food Retail group.
11/30/18
BOFA
11/30/18
DOWNGRADE
BOFA
Underperform
Sprouts Farmers Market downgraded to Underperform from Buy at BofA/Merrill
BofA/Merrill analyst Robert Ohems downgraded Sprouts Farmers Market to Underperform from Buy and cut its price target to $21 from $35 following CEO Amin Maredla's plans to leave the company. Ohems believes Maredla is leaving to pursue other interests, but said the transition comes at a difficult time given expectations Q4 and 1H 2019 are already expected to be challenging. The analyst expects Q4 margin headwinds from increased investments in technology, training and wages, which should persist into 1H 2019. Further, Ohems sees risk to the company's same-store-sales outlook due to produce deflation and lower comp contribution from new stores.
AMBA Ambarella
$33.83

-0.81 (-2.34%)

11/30/18
ROTH
11/30/18
NO CHANGE
Target $40
ROTH
Neutral
Ambarella price target raised to $40 from $35 at Roth Capital
Following Ambarella's Q3 results, Roth Capital analyst Suji Desilva said he believes the name represents a differentiated investment opportunity in low power video and computer vision processor. While revenue from newer CV products remains an intermediate-term opportunity, Desilva says he is encouraged by initial design wins in both surveillance and automotive. While he raises his price target to $40, he remains Neutral and will look for additional computer vision traction prior to getting more constructive in the name.
10/29/18
NORL
10/29/18
INITIATION
Target $38
NORL
Outperform
Ambarella initiated with an Outperform at Northland
Northland analyst Gus Richard initiated Ambarella with a Buy and $38 price target saying it is well positioned for growth of Computer Vision. Richard sees multiple catalysts over the next 12 months including the ramp of Computer Vision Products in 1H 2019, adoption in Security Camera market, automotive design wins, and reduced Consumer revenue headwinds.
08/31/18
MSCO
08/31/18
NO CHANGE
Target $50
MSCO
Overweight
Morgan Stanley bullishness on Ambarella computer vision opportunity still intact
Morgan Stanley analyst Joseph Moore said a large miss in Ambarella's consumer business, an auto program delay and trade tensions in surveillance will all likely test investor patience, but he remains bullish as his enthusiasm for the new computer vision opportunity has not waned. He thinks the company is hitting its milestones and still expects the company to be able to talk more specifically about autonomous driving customers later this year, Moore tells investors. While his view of the upside has not changed, the downside protection in the event that the company is less successful transitioning to computer vision has declined, added Moore, who keeps an Overweight rating on Ambarella shares but lowered his price target to $50 from $58.
08/31/18
STFL
08/31/18
NO CHANGE
Target $45
STFL
Buy
Ambarella price target lowered to $45 from $56 at Stifel
Stifel analyst Kevin Cassidy lowered his price target on Ambarella shares to $45 from $56 after the company guided for continued weakness in all consumer camera categories, which leaves him more cautious on the core business into FY20. However, he keeps a Buy rating on the stock, citing his positive view on the longer term prospects of Ambarella's computer vision SoCs. Management stated that the CV family is progressing in line with previous expectations and they expect initial CV revenue in the first half of next year, noted Cassidy.
VMW VMware
$161.63

1.78 (1.11%)

11/30/18
KEYB
11/30/18
NO CHANGE
Target $199
KEYB
Overweight
VMware price target raised to $199 from $167 at KeyBanc
KeyBanc analyst Alex Kurtz reiterated an Overweight rating on VMware and raised his price target to $199 from $167, citing strong initial FY20 guidance that was $400M above consensus. In a research note to investors, Kurtz says VMware delivered solid upside to license revenue at 17% y/y growth vs. consensus at 14% y/y, while total billings was closer to in line. The general macro discussion was positive on next year's IT spending, he says, adding that VMware is also executing well in growth segments like NSX, vSAN, and a growing pipeline of AWS-partnered hybrid cloud offerings.
11/30/18
JPMS
11/30/18
NO CHANGE
Target $194
JPMS
Overweight
VMware price target raised to $194 from $165 at JPMorgan
JPMorgan analyst Mark Murphy raised his price target for VMware to $194 saying the company last night delivered a "strong" Q3 and provided preliminary fiscal 2020 revenue guidance calling for 12% growth, "far above" consensus calling for 8.3% growth. This likely provide a "wake-up call about the trajectory of the business," Murphy tells investors in a research note. The analyst keeps an Overweight rating on VMware.
11/30/18
WEDB
11/30/18
NO CHANGE
Target $200
WEDB
Outperform
VMware price target raised to $200 from $185 at Wedbush
Wedbush analyst Daniel Ives maintained an Outperform rating on VMware following the company's "solid" Q3 results, which beat the Street on the heels of solid license growth. The analyst, who raises his price target to $200, says that Q3 ultimately takes a back seat to the company's initial FY20 guidance which was handily above the Street, which he calls a "major step in the right direction." While now it's about execution as the Dell overhang is in the rear view mirror, Ives says VMware is heading into year-end and FY20 with major tailwinds on both its existing core platform as well as new cloud products, "a key 1-2 punch" that should move the stock markedly higher.
11/30/18
RBCM
11/30/18
NO CHANGE
Target $200
RBCM
Outperform
VMware price target raised to $200 from $180 at RBC Capital
RBC Capital analyst Matthew Hedberg raised his price target on VMWare (VMW) to $200 and kept his Outperform rating after its "strong" Q3 results and initial FY20 outlook that calls for revenue growth of 12% - better than the consensus of 8%. The analyst believes that the results highlight the "impressive acceleration at scale and increasing role in driving customers' hybrid cloud initiatives", also raising his FY19 EPS view by 6c to $6.20 and FY20 by 5c to $6.73. Hedberg is also positive on VMWare's growing relationship with Amazon's (AMZN) AWS and the "potential for additional capital allocation beyond the current buyback", along with its "attractive valuation" and "under-owned" market status.
WDAY Workday
$145.55

-0.24 (-0.16%)

11/30/18
FBCO
11/30/18
NO CHANGE
Target $155
FBCO
Neutral
Workday price target raised to $155 from $150 at Credit Suisse
Credit Suisse analyst Brad Zelnick maintained a Neutral rating on Workday and raised his price target to $155 from $150 after reporting an "all-around clean quarter." In a research note to investors, Zelnick says that while he appreciates the company's continued success in HCM and early signs of success with Adaptive, he remains on the sidelines given Workday's premium valuation and until he sees sustained traction in Financials.
11/30/18
STFL
11/30/18
NO CHANGE
Target $160
STFL
Hold
Workday price target raised to $160 from $150 at Stifel
Stifel analyst Brad Reback said all of Workday's key financial metrics beat management's guidance and consensus estimates in Q3. He also noted that management raised FY19 guidance "once again" and issued an initial FY20 outlook ahead of consensus. While Reback said "there is no question that Workday is executing well...and gaining market share," he believes the stock is likely to perform in-line with peers in the near-future given its current valuation. He keeps a Hold rating on Workday, but raised his price target to $160 following the quarterly report.
11/30/18
BMOC
11/30/18
NO CHANGE
Target $170
BMOC
Market Perform
Workday price target raised to $170 from $165 at BMO Capital
BMO Capital analyst Keith Bachman raised his price target on Workday to $170 after the company posted its "strongest quarter of the year" with a "solid" beat on billings, revenues, and margins. The analyst adds that Workday confirmed its "solid pipeline" by growing its backlog by 31% from last year. While Bachmain maintains a positive outlook for the company based on its "accelerating growth potential", he also keeps his Market Perform rating on Workday as believes that the valuation on the stock "appears high".
11/30/18
RBCM
11/30/18
NO CHANGE
Target $170
RBCM
Outperform
Workday price target raised to $170 from $159 at RBC Capital
RBC Capital analyst Ross MacMillan raised his price target on Workday to $170 and kept his Outperform rating, saying the company's "strong" Q3 results saw accelerating bookings in Human Capital Management and Financials segments. The analyst believes that Workday's FY20 initial guidance also looks "prudent", implying a 23% organic growth that he sees as "conservative" in the context of new business signings and pipeline commentary. MacMillan also raises his FY19 EPS view by 20c to $1.25 and revenue view to $2.81B from $2.77B.
SPLK Splunk
$102.00

2.77 (2.79%)

11/30/18
JEFF
11/30/18
NO CHANGE
Target $137
JEFF
Buy
Splunk raised guidance by more than the Q3 beat, says Jefferies
Splunk exceeded fiscal Q3 expectations, raised fiscal 2019 by more than the beat, and raised its outlook for fiscal 2020, Jefferies analyst John DiFucci tells investors in a post-earnings research note. The analyst continues to view the company as a "unique asset" that represents one of the best ways to play the Big Data theme. Further, he believes the underlying business is likely stronger than it appears. The analyst keeps a Buy rating on Splunk with a $137 price target.
11/30/18
MUFG
11/30/18
NO CHANGE
Target $130
MUFG
Overweight
Splunk target raised to $130 on 'solid momentum' at MUFG
MUFG analyst Stephen Bersey raised his price target for Splunk to $130 from $128 saying the company's "streak of solid momentum continues." The analyst views last night's fiscal Q3 results as "strong," marked by a re-acceleration of license revenue growth to 44.3% year-over-year, the highest level of the fiscal year thus far. Splunk still has a long runway of growth ahead of it as its core business solutions continue to gain traction within the enterprise vertical and as the company continues to roll out new products and solutions, Bersey tells investors in a post-earnings research note. He reiterates an Overweight rating on the name.
11/27/18
BMOC
11/27/18
NO CHANGE
Target $133
BMOC
Outperform
Splunk demand trends remain solid, says BMO Capital
BMO Capital analyst Keith Bachman kept his Outperform rating and $133 price target on Splunk, saying there is "upside tension" to his and to consensus estimates for October quarter billings and revenues based on the company's "solid demand trends". The analyst also anticipates the company to provide strong January quarter guidance and for the management to "devote considerable attention to billings duration on the upcoming earnings call" to answer investors' concerns about its billings duration. Bachman further points to Splunk's attractive valuation, with the stock currently trading at about 6.5-times enterprise value to revenue multiple, which is about 6% below its 3-year average.
11/30/18
PIPR
11/30/18
NO CHANGE
Target $130
PIPR
Overweight
Splunk price target raised to $130 from $120 at Piper Jaffray
Piper Jaffray analyst Alex Zukin raised his price target for Splunk to $130 and reiterates an Overweight rating on the shares. The analyst says the company last night posted the quarter he was were looking for, with its largest quarterly revenue beat in five years coupled with guidance that outperformed both in the current year and for fiscal 2020. Splunk's fundamentals continue to improve and it remains a "strategic asset trading at a discounted valuation," Zukin tells investors in a post-earnings research note titled "F3Q19 Earnings: Doug E. Fresh With the Beat as King Conte Drops the Mic."
HIMX Himax
$4.11

0.08 (1.99%)

11/08/18
BARD
11/08/18
NO CHANGE
BARD
Himax price target lowered to $7 from $10 at Baird
Baird analyst Tristan Gerra maintained an Outperform rating on Himax, but removed his Fresh Pick label and lowered his price target on shares to $7 from $10, citing the longer-term nature of Himax's catalysts and continued 3D sensing pushouts. The analyst noted that 3D sensing adoption at Chinese smartphone OEMs will "likely remain minimal next year."
11/09/18
FBCO
11/09/18
DOWNGRADE
FBCO
Neutral
Himax downgraded to Neutral from Outperform at Credit Suisse
11/20/18
ROTH
11/20/18
DOWNGRADE
ROTH
Neutral
Himax downgraded to Neutral from Buy at Roth Capital
11/20/18
11/20/18
DOWNGRADE
Target $4

Neutral
Himax downgraded to Neutral on reduced visibility at Roth Capital
As previously reported, Roth Capital analyst Suji Desilva downgraded Himax to Neutral from Buy given reduced visibility as smartphone manufacturers work through inventory of devices built in Q3. Desilva believes that flagship smartphone orders for WLO parts has softened in recent weeks and that China smartphone demand remains soft. Given the smartphone softness and reduced visibility, Desilva lowered the price target on Himax shares to $4 from $7.
LH LabCorp
$161.78

-3.22 (-1.95%)

10/30/18
10/30/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. LabCorp (LH) downgraded to Hold from Buy at Argus with analyst Jasper Hellweg saying the company is faced with pressure from "lower lab testing payment rates mandated by the Protecting Access to Medicaid Act of 2014" along with business disruptions and the impact of acquisitions which resulted in lowers margins for the quarter. 2. E-Trade (ETFC) downgraded to Outperform from Strong Buy at Raymond James with analyst Patrick O'Shaughnessy saying the recent board decision not to sell the business and remain a standalone company takes a sales scenario off the table. The analyst remains positive on shares ans believes there is plenty of upside as management executes on its operating plan. 3. Southwest (LUV) downgraded to Underweight from Neutral at JPMorgan while United Continental (UAL) and Spirit Airlines (SAVE) downgraded to Neutral from Overweight. 4. Flex (FLEX) downgraded to Hold from Buy at Argus with analyst Jim Kelleher citing the expected impact from the "shutdown of Mexican operations with key customer Nike (NKE), which he expects to be fully unwound," as well as the retirement of the company CEO Mike McNamara who had presided over the company's business expansion. 5. Elevate Credit (ELVT) downgraded to Market Perform from Outperform at JMP Securities and William Blair. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/28/18
PIPR
11/28/18
NO CHANGE
PIPR
Piper sees 'incremental winners' in final Clinical Laboratory Fee Schedule
CareDx (CDNA), Genomic Health (GHDX), LabCorp (LH), Myriad Genetics (MYGN), Natera (NTRA) and Quest Diagnostics (DGX) are the "incremental winners" in the 2019 Final Clinical Laboratory Fee Schedule determinations announced by the Centers for Medicare and Medicaid Services, Piper Jaffray analyst William Quirk tells investors in a research note. Specifically, CMS priced the advanced carrier screening panel at $2,449 versus the code stack method yesterday, Quirk writes. He points out that Genomic Health gets a bump for a couple tests and CareDx competitor TAI Diagnostics ends up with a likely longer pathway to reimbursement.
11/30/18
GSCO
11/30/18
DOWNGRADE
Target $180
GSCO
Buy
LabCorp downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Patrick Donnelly removed LabCorp from his firm's Americas Conviction List and lowered his price target for the shares to $180 from $190. He keeps a Buy rating on the stock. The analyst also downgraded his coverage view of Labs from Attractive to Neutral. His "incrementally more cautious stance" reflects his expectation for continued downward pressure to consensus estimates from ongoing pricing pressure, a "muted" volume outlook, and uncertainty regarding ongoing commercial payer dynamics. However, he believes LabCorp is "uniquely positioned to offset Lab industry headwinds."
11/30/18
GSCO
11/30/18
DOWNGRADE
Target $90
GSCO
Neutral
Quest Diagnostics downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Patrick Donnelly downgraded Quest Diagnostics (DGX) to Neutral and lowered his price target for the shares to $90 from $110. The analyst also downgraded his coverage view of Labs from Attractive to Neutral and removed LabCorp (LH) from his firm's Americans Conviction List. Donnelly's "incrementally more cautious stance" reflects his expectation for continued downward pressure to consensus estimates from ongoing pricing pressure, a "muted" volume outlook, and uncertainty regarding ongoing commercial payer dynamics. He sees an "uneven path to long-term organic volume growth" for Quest.
GME GameStop
$14.65

-0.37 (-2.46%)

11/29/18
BARD
11/29/18
NO CHANGE
Target $14
BARD
Outperform
GameStop quarter 'mixed' on disappointing pre-owned segment sales, says Baird
Baird analyst Colin Sebastian writes that GameStop Q3 results have come in mixed, with better than expected earnings but a lowered Q4 guidance given the "weakness in pre-owned sales and underperformance from recent sales promotions." The analyst states that the low guidance reflects the company's mix shift toward lower-margin hardware from high-margin software. Sebastian also keeps his Outperform rating and $14 price target on GameStop, adding that "importantly", the company is still in "discussions regarding potential strategic alternatives, including a potential sale".
11/30/18
LOOP
11/30/18
NO CHANGE
Target $13
LOOP
Hold
GameStop price target lowered to $13 from $15 at Loop Capital
Loop Capital analyst Anthony Chukumba lowered his price target on GameStop to $13 and kept his Hold rating after its Q3 results, saying he found the guidance reduction for the rest of 2018 as "troubling", particularly the "dramatic reduction" in its free cash flows. The analyst notes that the current "secular headwinds" give him little hope that performance will improve significantly any time soon.
11/30/18
WEDB
11/30/18
NO CHANGE
Target $18
WEDB
Outperform
GameStop sale to private equity 'imminent,' says Wedbush
Wedbush analyst reiterated an Outperform rating and $18 price target on GameStop following the company's mixed Q3 results and lowered FY18 guidance, telling investors in a research note that the threat from the digital mix shift is being overshadowed by the proposed Spring Mobile sale. Additionally, the analyst says he believes that a sale of GameStop to private equity is "imminent," as he thinks that if the continuation of GameStop as a standalone entity were a likelihood, the company would have identified CEO candidates since the departure of its CEO over six months ago.
11/30/18
BNCH
11/30/18
NO CHANGE
Target $9
BNCH
Sell
GameStop 'has zero terminal value,' says Benchmark
Benchmark analyst Mike Hickey said he was not surprised that GameStop reduced its FY18 earnings view and free cash flow guidance given the weaker than anticipated new/used software sales, higher promotional expenses and a mix shift towards lower margin hardware sales evidenced in its Q3 report. The company appears "lost at sea" and its management team "lacks investor credibility," said Hickey, who believes GameStop "has zero terminal value." He sees the "Hail Mary" effort to sell the remainder of the company running up against "limited reasonable financial outcomes that would encourage a potential bid," Hickey added. The analyst keeps a Sell rating on GameStop shares and lowered his price target on the stock to $9 from $10.
PVH PVH Corp.
$109.82

-1.15 (-1.04%)

11/19/18
FBCO
11/19/18
NO CHANGE
Target $150
FBCO
Outperform
PVH Corp. price target lowered to $150 from $185 at Credit Suisse
Credit Suisse analyst Michael Binetti lowered his price target for PVH Corp. to $150 from $185 following quarterly results as the company navigates a rockier near-term path. The analyst reiterates an Outperform rating on the shares.
11/30/18
FBCO
11/30/18
NO CHANGE
Target $125
FBCO
Outperform
PVH Corp. price target cut to $125 from $150 at Credit Suisse
Credit Suisse analyst Michael Binetti reiterated an Outperform rating on PVH Corp but lowered his price target to $125 from $150 following the company's Q3 results. In a research note to investors, Binetti says he was "disheartened" by a "big" gross margin miss at Calvin Klein, as the company had to clear slow-selling CK Jeans/Collection product. Looking ahead, he expects PVH to speak to a long-awaited CK margin improvement in 2019 vs. three yrs of declines, which he thinks can go a long way to stabilizing the profit outlook.
11/30/18
KING
11/30/18
UPGRADE
KING
Strong Buy
PVH Corp. upgraded to Strong Buy from Buy at CL King
11/30/18
PIPR
11/30/18
NO CHANGE
Target $150
PIPR
Overweight
PVH Corp. price target lowered to $150 from $175 at Piper Jaffray
Piper Jaffray analyst Erinn Murphy lowered her price target for PVH Corp. to $150 saying the earnings beat in Q3 was overshadowed by the Calvin Klein Jeans and Collection miss. The analyst believes management will need to answer to questions regarding the health of the CK brand health along with product and marketing plans going forward. She adjusted her estimates but keeps an Overweight rating on PVH Corp.

TODAY'S FREE FLY STORIES

CVET

Covetrus

$14.93

1.44 (10.67%)

18:41
11/15/19
11/15
18:41
11/15/19
18:41
Hot Stocks
Covetrus CEO: We're a leader in the humanization of pets »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSK

Comcast

$0.00

(0.00%)

, CMCSA

Comcast

$44.54

-0.93 (-2.05%)

18:02
11/15/19
11/15
18:02
11/15/19
18:02
Hot Stocks
Viacom extends cable deal for 'The Office' through 2025 »

Viacom (VIA) announced…

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

VIAB

Viacom

$23.07

0.59 (2.62%)

VIA

Viacom

$26.59

1.28 (5.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CWK

Cushman & Wakefield

$19.10

0.1 (0.53%)

17:48
11/15/19
11/15
17:48
11/15/19
17:48
Hot Stocks
Cushman & Wakefield CEO sells 84.6K share of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

LMT

Lockheed Martin

$393.52

3.305 (0.85%)

17:39
11/15/19
11/15
17:39
11/15/19
17:39
Hot Stocks
Lockheed Martin awarded maximum $3.33B Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESCA

Escalade

$10.90

-0.09 (-0.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Escalade CEO Fetherman to retire »

Escalade announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.96

0.1 (0.78%)

, ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Eldorado, Caesars stockholders approve Eldorado acquisition of Caesars »

Eldorado Resorts (ERI)…

CZR

Caesars

$12.96

0.1 (0.78%)

ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EGRX

Eagle Pharmaceuticals

$57.24

0.55 (0.97%)

17:15
11/15/19
11/15
17:15
11/15/19
17:15
Syndicate
Breaking Syndicate news story on Eagle Pharmaceuticals »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$60.82

0.84 (1.40%)

17:11
11/15/19
11/15
17:11
11/15/19
17:11
Hot Stocks
Fabrinet President Gill sells 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

TEUM

Pareteum

$0.38

-0.0209 (-5.21%)

17:05
11/15/19
11/15
17:05
11/15/19
17:05
Hot Stocks
Pareteum receives noncompliance notice from Nasdaq »

Pareteum announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEXO

Hexo

$1.78

-0.1 (-5.32%)

17:00
11/15/19
11/15
17:00
11/15/19
17:00
Hot Stocks
Hexo was cannabis was being grown in unlicensed space at Niagara site »

HEXO Corp provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$220.84

2.29 (1.05%)

, CELG

Celgene

$110.02

-0.01 (-0.01%)

16:57
11/15/19
11/15
16:57
11/15/19
16:57
Hot Stocks
Bristol-Myers gets FTC clearance for Celgene acquisition »

Bristol-Myers Squibb…

AMGN

Amgen

$220.84

2.29 (1.05%)

CELG

Celgene

$110.02

-0.01 (-0.01%)

BMY

Bristol-Myers

$58.61

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 04

    Dec

  • 07

    Dec

  • 25

    Mar

  • 04

    Apr

RAVE

Rave Restaurant

$1.44

-0.79 (-35.43%)

16:47
11/15/19
11/15
16:47
11/15/19
16:47
Hot Stocks
BBRC Asset Management reports 6.6% passive stake in Rave Restaurant »

BBRC Asset Management …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHAP

Chaparral Energy

$0.89

-0.0521 (-5.52%)

16:46
11/15/19
11/15
16:46
11/15/19
16:46
Hot Stocks
Chaparral Energy receives continued listing standard notice from NYSE »

Chaparral Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

CI

Cigna

$196.08

6.41 (3.38%)

, CNC

Centene

$57.57

2.91 (5.32%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks closed out the…

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

NVDA

Nvidia

$204.12

-5.76 (-2.74%)

AMZN

Amazon.com

$1,739.33

-15.38 (-0.88%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

UAA

Under Armour

$17.78

0.65 (3.79%)

UA

Under Armour

$15.97

0.41 (2.64%)

AMRN

Amarin

$23.99

2.5 (11.63%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

GOOG

Alphabet

$1,334.01

21.82 (1.66%)

GOOGL

Alphabet Class A

$1,333.33

23.54 (1.80%)

ORCL

Oracle

$56.43

0.33 (0.59%)

RH

RH

$188.73

13.535 (7.73%)

QGEN

Qiagen

$40.56

3.255 (8.73%)

FTCH

Farfetch

$9.66

2.17 (28.97%)

THC

Tenet

$30.55

1.08 (3.66%)

TORC

resTORbio

$1.10

-6.83 (-86.13%)

ACB

Aurora Cannabis

$2.72

-0.57 (-17.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 28

    Dec

  • 06

    Jan

  • 21

    Jan

  • 06

    Feb

NYT

New York Times

$31.60

0.44 (1.41%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
New York Times CEO sells 66,000 class A common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

WEX

Wex

$200.52

4.61 (2.35%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
Wex director Morris sells 3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBLI

Cleveland BioLabs

$0.59

-0.0444 (-6.97%)

16:39
11/15/19
11/15
16:39
11/15/19
16:39
Hot Stocks
Cleveland BioLabs CEO resigns effective December 13th »

In a regulatory 8-K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGC

LogicBio Therapeutics

$9.29

-0.04 (-0.43%)

16:38
11/15/19
11/15
16:38
11/15/19
16:38
Syndicate
Breaking Syndicate news story on LogicBio Therapeutics »

LogicBio Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTBI

HomeTrust

$25.99

-0.31 (-1.18%)

16:38
11/15/19
11/15
16:38
11/15/19
16:38
Hot Stocks
HomeTrust raises quarterly dividend 17% to 7c per share »

HomeTrust Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

FR

First Industrial Realty

$42.05

-0.03 (-0.07%)

16:36
11/15/19
11/15
16:36
11/15/19
16:36
Hot Stocks
First Industrial Realty director sells 12K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSI

United Bankshares

$39.51

-0.19 (-0.48%)

16:31
11/15/19
11/15
16:31
11/15/19
16:31
Hot Stocks
United Bankshares declares Q4 dividend of 35c per share »

United Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
11/15/19
11/15
16:30
11/15/19
16:30
Options
Preliminary option volume of 24.0M today »

Preliminary option volume…

16:25
11/15/19
11/15
16:25
11/15/19
16:25
Conference/Events
Federal Reserve Bank of San Francisco participates in a discussion »

San Francisco Federal…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.